GBIO Generation Bio Corp: Operatsion rentabellik

Generation Bio Co. - GBIO emitenti grafik logotipi

Generation Bio Co. (GBIO) ko'z va jigar patologiyalarini davolash uchun virusga asoslanmagan DNK yetkazib berish usullarini ishlab chiqmoqda. Kelajakdagi daromadlar genetik kasalliklarning takroriy davolanishini imkon qiluvchi ceDNA platformasining tijoratlashtirilishiga asoslangan. Kompaniya hozirda tijoratdan oldingi bosqichda bo'lib, bu tashqi moliyalashtirish faqat kapital xarajatlarini yumshatishga xizmat qilishini anglatadi. Choraklik operatsion marja samaradorlik tendentsiyalarini aniq namoyish etadi, bunda -512.50 qiymati metrika darajasini ifodalaydi.

GBIO - Generation Bio Co Operatsion foyda normasi 04.07.2022 - 21.02.2026 oraligʻida

Generation Bio Co. (GBIO) kompaniyasi koʻrsatkichlari kesimi va tahlili

- aksiya narxi va baholash bo'yicha konsensus prognoz:
- kompaniya aksiyalari kapitallashuvi ma'lumotlari:
Kompaniyaning dastlabki tahlili:Generation Bio, GBIO
Generation Bio Corp asosiy tovari

O'zining noyob DNK platformalarini patentlar bilan himoya qiluvchi Generation Bio Co. (GBIO) uchun salbiy marja FDA ning qat'iy nazorati ostidagi kapitalga intensiv rivojlanish bosqichini aks ettiradi. Operatsion foyda marjalarining tahlili barcha xarajatlar chegirib tashlanganidan keyingi operatsion daromad ulushini, qarz yuklamasi va soliqlarning ta'sirini hisobga olmagan holda baholash imkonini beradi, bu esa joriy daromadlilikdan ko'ra texnologiyalarni kengaytirishning strategik ustuvorligini tasdiqlaydi.

Generation Bio Co. (GBIO) raqobatchilari

Sotuvning operatsion marjasi TEM|QGEN - Operatsion foyda bo'yicha marjinallik|Operatsion marja IONS|RGEN - Sotuvning operatsion rentabelligi|Operatsion rentabellik Avidity RNA|Operatsion marja CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operatsion marja|Ultragenyx Pharma (RARE) - Sotuvning operatsion marjasi|beamtx.com (BEAM) - Operatsion rentabellik|SRPT: Operatsion foyda koeffitsiyenti|Sotuvning operatsion marjasi TWST|TXG - Operatsion foyda bo'yicha marjinallik|Operatsion marja NTLA|Operatsion faoliyat rentabelligi Stoke Therapeutics|Operatsion rentabellik BioLife Solutions BLFS|Wave Life Sciences (WVE) - Sotuvning operatsion rentabelligi|Maze Therapeutics, Inc. - Operatsion marja|Operatsion faoliyat rentabelligi Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Operatsion rentabellik|TSHA: Operatsion foyda koeffitsiyenti|Operatsion rentabellik uniQure Pharma|MGTX - Operatsion foyda bo'yicha marjinallik|Operatsion marja RGNX|Operatsion rentabellik SLDB (Solid Biosciences)|Ocugen Corp - Sotuvning operatsion marjasi|PACB: Operatsion foyda bo'yicha sotuv rentabelligi|benitec.com - Operatsion marja|DSGN - Operatsion marja|RCKT: Operatsion marja|FDMT (4D Molecular Therapeutics Inc) - Operatsion rentabellik|Sotuvning operatsion marjasi LXEO|Operatsion rentabellik KRRO|Operatsion marja EDIT|SLN - Sotuvning operatsion rentabelligi|Operatsion marja PRQR (ProQR)|CDXS - Sotuvning operatsion marjasi|Sangamo Therapeutics Inc. - Operatsion marja|NAUT - Operatsion marja|MGX: Operatsion marja|Sotuvning operatsion marjasi Precision BioSciences, Inc.|Operatsion rentabellik Boundless Bio Inc.|Sotuvning operatsion marjasi Exicure (XCUR)|Operatsion marja IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operatsion foyda normasi|Mustang Bio, Inc. - Sotuvning operatsion marjasi|RNAZ - Sotuvning operatsion marjasi|BNGO: Sotuvning operatsion marjasi|APDN (Applied DNA Sciences Inc) - Operatsion foyda bo'yicha sotuv rentabelligi|BLUE (Bluebird Bio) - Sotuvning operatsion marjasi|ImmunoPrecise Antibodies Ltd - Operatsion foyda normasi|OMGA (Omega Therapeutics Inc) - Operatsion marja|Operatsion rentabellik OMIC|Operatsion rentabellik Regulus Therapeutics Inc. (RGLS)|Sotuvning operatsion marjasi Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Sotuvning operatsion marjasi|Operatsion foyda normasi TCON|UBX - Operatsion rentabellik